These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1219 related articles for article (PubMed ID: 10780580)

  • 1. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview.
    Dobrilla G; Di Fede F
    Clin Ther; 1993; 15 Suppl B():2-13. PubMed ID: 7911400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term management of gastroesophageal reflux disease and its complications.
    Richter JE
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):30S-34S; discussion 34S-35S. PubMed ID: 9127624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acid suppression therapy: where do we go from here?
    Scarpignato C; Pelosini I; Di Mario F
    Dig Dis; 2006; 24(1-2):11-46. PubMed ID: 16699262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
    Bardhan KD
    Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastroesophageal reflux disease: pathophysiology and pharmacology overview.
    Dajani EZ
    J Assoc Acad Minor Phys; 2000; 11(1):7-11. PubMed ID: 10826019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic approaches to healing esophagitis.
    Boyce HW
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):22S-27S; discussion 27S-29S. PubMed ID: 9127623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs, bugs, and esophageal pH profiles.
    Robinson M
    Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis.
    Fiorucci S; Santucci L; Morelli A
    Am J Gastroenterol; 1990 Nov; 85(11):1458-62. PubMed ID: 2239873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors.
    Pfefferkorn MD; Croffie JM; Gupta SK; Molleston JP; Eckert GJ; Corkins MR; Fitzgerald JF
    J Pediatr Gastroenterol Nutr; 2006 Feb; 42(2):160-5. PubMed ID: 16456408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy of gastroesophageal reflux disease in secondary and tertiary care settings.
    Tytgat GN
    Yale J Biol Med; 1999; 72(2-3):219-26. PubMed ID: 10780584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
    Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K
    Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of action of antisecretory drugs: beneficial effects of a rapid increase in intragastric pH in acid reflux disease.
    Pipkin GA; Mills JG
    Scand J Gastroenterol Suppl; 1999; 230():3-8. PubMed ID: 10499455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
    Miner PB
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
    Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
    Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.